Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study (vol 169, pg 534, 2015)

被引：1
|
作者：
Swords, R. T.
机构：
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2015年 / 171卷 / 02期
关键词：
D O I：
10.1111/bjh.13775
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：294 / 294
页数：1
相关论文
共 50 条
  • [1] Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study
    Swords, Ronan T.
    Erba, Harry P.
    DeAngelo, Daniel J.
    Bixby, Dale L.
    Altman, Jessica K.
    Maris, Michael
    Hua, Zhaowei
    Blakemore, Stephen J.
    Faessel, Helene
    Sedarati, Farhad
    Dezube, Bruce J.
    Giles, Francis J.
    Medeiros, Bruno C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 169 (04) : 534 - 543
  • [2] MLN4924: a novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapy
    Nawrocki, Steffan T.
    Griffin, Patrick
    Kelly, Kevin R.
    Carew, Jennifer S.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2012, 21 (10) : 1563 - 1573
  • [3] MLN4924, a First-in-Class NEDD8-Activating Enzyme Inhibitor, Attenuates IFN-β Production
    Song, Hui
    Huai, Wanwan
    Yu, Zhongxia
    Wang, Wenwen
    Zhao, Jing
    Zhang, Lining
    Zhao, Wei
    JOURNAL OF IMMUNOLOGY, 2016, 196 (07): : 3117 - 3123
  • [4] Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes
    R T Swords
    J Watts
    H P Erba
    J K Altman
    M Maris
    F Anwer
    Z Hua
    H Stein
    H Faessel
    F Sedarati
    B J Dezube
    F J Giles
    B C Medeiros
    D J DeAngelo
    Blood Cancer Journal, 2017, 7 : e520 - e520
  • [5] Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes
    Swords, R. T.
    Watts, J.
    Erba, H. P.
    Altman, J. K.
    Maris, M.
    Anwer, F.
    Hua, Z.
    Stein, H.
    Faessel, H.
    Sedarati, F.
    Dezube, B. J.
    Giles, F. J.
    Medeiros, B. C.
    DeAngelo, D. J.
    BLOOD CANCER JOURNAL, 2017, 7 : e520 - e520
  • [6] Targeting the protein ubiquitination machinery in melanoma by the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924)
    Wong, Kit Man
    Micel, Lindsey N.
    Selby, Heather M.
    Tan, Aik Choon
    Pitts, Todd M.
    Bagby, Stacey M.
    Spreafico, Anna
    Klauck, Peter J.
    Blakemore, Stephen J.
    Smith, Peter F.
    McDonald, Alice
    Berger, Allison
    Tentler, John J.
    Eckhardt, S. Gail
    INVESTIGATIONAL NEW DRUGS, 2017, 35 (01) : 11 - 25
  • [7] Targeting the protein ubiquitination machinery in melanoma by the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924)
    Kit Man Wong
    Lindsey N. Micel
    Heather M. Selby
    Aik Choon Tan
    Todd M. Pitts
    Stacey M. Bagby
    Anna Spreafico
    Peter J. Klauck
    Stephen J. Blakemore
    Peter F. Smith
    Alice McDonald
    Allison Berger
    John J. Tentler
    S. Gail Eckhardt
    Investigational New Drugs, 2017, 35 : 11 - 25
  • [8] The novel, investigational Nedd8-activating enzyme inhibitor MLN4924 in patients with metastatic melanoma: a phase 1 study
    Hamid, O.
    Dezube, B. J.
    Pickard, M. D.
    Shultz, M. A.
    Bhatia, S.
    EJC SUPPLEMENTS, 2010, 8 (07): : 130 - 130
  • [9] The Novel, Investigational NEDD8-Activating Enzyme Inhibitor MLN4924 In Adult Patients with Acute Myeloid Leukemia (AML) or High-Grade Myelodysplastic Syndromes (MDS): A Phase 1 Study
    Swords, Ronan T.
    Erba, Harry P.
    DeAngelo, Daniel J.
    Smith, Peter G.
    Pickard, Michael D.
    Dezube, Bruce J.
    Giles, Francis J.
    Medeiros, Bruno C.
    BLOOD, 2010, 116 (21) : 288 - 288
  • [10] A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma
    Bhatia, Shailender
    Pavlick, Anna C.
    Boasberg, Peter
    Thompson, John A.
    Mulligan, George
    Pickard, Michael D.
    Faessel, Helene
    Dezube, Bruce J.
    Hamid, Omid
    INVESTIGATIONAL NEW DRUGS, 2016, 34 (04) : 439 - 449
12345